Talphera Reports Q4 Loss, Higher 2026 Expenses Amid 50% Clinical Trial Enrollment
Summary
Talphera announced its fourth quarter and full year 2025 financial results, reporting a Q4 net loss of $3.8 million ($0.06 per share) and a cash balance of $20.4 million as of December 31, 2025. The company also provided 2026 guidance, projecting cash operating expenses of $17 million to $18 million, a notable increase from approximately $13 million in 2025. Operationally, Talphera achieved a significant milestone with 50% enrollment in its NEPHRO CRRT clinical study. This update follows a recent Nasdaq notice on March 13 regarding the company's failure to meet the minimum $1.00 bid price requirement, highlighting ongoing financial challenges. While the $4.1 million private placement closing mentioned in the update was previously reported on March 16, the financial results, increased expense guidance, and clinical progress are new and material. For a small-cap biotech company facing delisting concerns, these financial results and operational updates are critical, as the increased cash burn will impact its runway. Investors will be closely watching the company's cash position, further progress in the NEPHRO CRRT study, and strategies to address the Nasdaq deficiency.
At the time of this announcement, TLPH was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.8M. The 52-week trading range was $0.38 to $1.57. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.